CymaBay Therapeutics Inc (CBAY) Director Sells $43,903.00 in Stock

CymaBay Therapeutics Inc (NASDAQ:CBAY) Director Kurt Von Emster sold 4,300 shares of CymaBay Therapeutics stock in a transaction on Friday, January 5th. The shares were sold at an average price of $10.21, for a total transaction of $43,903.00. Following the completion of the sale, the director now owns 90,000 shares in the company, valued at $918,900. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Kurt Von Emster also recently made the following trade(s):

  • On Wednesday, January 31st, Kurt Von Emster sold 97,639 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $12.22, for a total transaction of $1,193,148.58.
  • On Thursday, January 25th, Kurt Von Emster sold 39,438 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $12.18, for a total transaction of $480,354.84.
  • On Monday, January 22nd, Kurt Von Emster sold 138,253 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $10.40, for a total transaction of $1,437,831.20.
  • On Friday, January 19th, Kurt Von Emster sold 144,216 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $10.25, for a total transaction of $1,478,214.00.
  • On Friday, December 22nd, Kurt Von Emster sold 173,192 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $9.41, for a total transaction of $1,629,736.72.
  • On Friday, November 10th, Kurt Von Emster sold 50,048 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $9.26, for a total transaction of $463,444.48.
  • On Tuesday, October 31st, Kurt Von Emster sold 59,209 shares of CymaBay Therapeutics stock. The stock was sold at an average price of $9.27, for a total transaction of $548,867.43.

CymaBay Therapeutics Inc (NASDAQ CBAY) traded down $0.05 during mid-day trading on Friday, hitting $12.03. 633,482 shares of the company were exchanged, compared to its average volume of 798,589. CymaBay Therapeutics Inc has a 52-week low of $1.83 and a 52-week high of $12.60. The company has a debt-to-equity ratio of 0.04, a quick ratio of 7.39 and a current ratio of 7.39. The stock has a market cap of $527.69, a PE ratio of -11.91 and a beta of 2.04.

CymaBay Therapeutics (NASDAQ:CBAY) last released its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.02). During the same quarter in the prior year, the firm earned ($0.25) EPS. equities research analysts predict that CymaBay Therapeutics Inc will post -0.87 earnings per share for the current fiscal year.

A number of equities analysts have commented on CBAY shares. Oppenheimer set a $15.00 price objective on shares of CymaBay Therapeutics and gave the stock a “buy” rating in a research note on Wednesday, January 10th. Zacks Investment Research cut shares of CymaBay Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, January 16th. HC Wainwright reaffirmed a “buy” rating and set a $12.00 price target on shares of CymaBay Therapeutics in a research note on Tuesday, November 28th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $12.00 price target on shares of CymaBay Therapeutics in a research note on Friday, October 27th. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $16.00 price target on shares of CymaBay Therapeutics in a research note on Wednesday, November 8th. Two equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. CymaBay Therapeutics currently has a consensus rating of “Buy” and an average price target of $16.56.

A number of institutional investors have recently added to or reduced their stakes in the business. Schwab Charles Investment Management Inc. purchased a new stake in CymaBay Therapeutics in the 4th quarter valued at about $115,000. GSA Capital Partners LLP purchased a new stake in CymaBay Therapeutics in the 3rd quarter valued at about $1,218,000. Iguana Healthcare Management LLC boosted its position in CymaBay Therapeutics by 138.1% in the 3rd quarter. Iguana Healthcare Management LLC now owns 250,000 shares of the biopharmaceutical company’s stock valued at $2,015,000 after buying an additional 145,000 shares during the period. Crestline Management LP purchased a new stake in CymaBay Therapeutics in the 3rd quarter valued at about $841,000. Finally, Perceptive Advisors LLC purchased a new stake in CymaBay Therapeutics in the 3rd quarter valued at about $18,948,000. 69.15% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This report was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/02/kurt-von-emster-sells-4300-shares-of-cymabay-therapeutics-inc-cbay-stock.html.

About CymaBay Therapeutics

CymaBay Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout.

Insider Buying and Selling by Quarter for CymaBay Therapeutics (NASDAQ:CBAY)

Receive News & Ratings for CymaBay Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CymaBay Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply